Narinder Singh
Directeur Technique/Scientifique/R&D chez ARCELLX, INC.
Profil
Narinder Singh is currently the Chief Technology Officer at Arcellx, Inc. He previously worked as the VP-Drug Product Development & Manufacturing at Momenta Pharmaceuticals, Inc. from 2015 to 2018, and as the Senior VP-Pharmaceutical Sciences & Manufacturing at Genocea Biosciences, Inc. from 2018 to 2020.
From 2020 to 2021, he was the Head-Technical Operations at Aimmune Therapeutics, Inc. He also briefly served as the Chief Technology Officer at Forte Biosciences, Inc. in 2021.
Mr. Singh received his undergraduate and graduate degrees from the Indian Institute of Technology New Delhi in 1994 and 1995, respectively.
He also received a graduate degree from the University of Houston in 1997 and an MBA from UCLA Anderson School of Management in 2004.
Postes actifs de Narinder Singh
| Sociétés | Poste | Début |
|---|---|---|
| ARCELLX, INC. | Directeur Technique/Scientifique/R&D | 01/10/2021 |
Anciens postes connus de Narinder Singh
| Sociétés | Poste | Fin |
|---|---|---|
| FORTE BIOSCIENCES, INC. | Directeur Technique/Scientifique/R&D | 01/10/2021 |
| AIMMUNE THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/07/2021 |
| GENOCEA BIOSCIENCES, INC. | Corporate Officer/Principal | 01/07/2020 |
| MOMENTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/03/2018 |
Formation de Narinder Singh
| Indian Institute of Technology New Delhi | Graduate Degree |
| University of Houston | Graduate Degree |
| UCLA Anderson School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| ARCELLX, INC. | Health Technology |
| FORTE BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Aimmune Therapeutics, Inc.
 Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
